Development of a bladder instilllation of the indoloquinone anticancer agent EO-9 using tert-butyl alcohol as lyophilization vehicle

AAPS PharmSciTech

Volumn 8, Issue 3, 2007, Pages

  van der Schoot, Sabien C ^a   Nuijen, Bastiaan ^a   Flesch, Frits M ^b   Gore, Ashok ^c   Mirejovsky, Dorla ^c   Lenaz, Luigi ^c   Beijnen, Jos H ^a,b  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

^b UTRECHT UNIVERSITY   (Netherlands)

^c Spectrum Pharmaceuticals   (United States)

Author keywords

EO 9; Formulation development; Freeze drying; Mitomycin analogue; Tert butyl alcohol

Indexed keywords

5 (1 AZIRIDINYL) 3 HYDROXYMETHYL 2 (3 HYDROXY 1 PROPENYL) 1 METHYL 4,7 INDOLEDIONE; ANTINEOPLASTIC AGENT; BICARBONATE; EDETATE SODIUM; MANNITOL; PROPYLENE GLYCOL; TERT BUTYL ALCOHOL; WATER; AZIRIDINE DERIVATIVE; DRUG VEHICLE; INDOLE DERIVATIVE;

ARTICLE; BLADDER CANCER; BLADDER IRRIGATION; CRYSTALLIZATION; DIFFERENTIAL SCANNING CALORIMETRY; DRUG DELIVERY SYSTEM; DRUG DETERMINATION; DRUG FORMULATION; DRUG MANUFACTURE; DRUG SOLUBILITY; DRUG STABILITY; DRUG STRUCTURE; FREEZE DRYING; PROCESS OPTIMIZATION; SCANNING ELECTRON MICROSCOPY; STRUCTURE ANALYSIS; X RAY DIFFRACTION; CHEMISTRY; GAS CHROMATOGRAPHY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; INTRAVESICAL DRUG ADMINISTRATION; SOLUBILITY; VEHICLES;

ADMINISTRATION, INTRAVESICAL; ANTINEOPLASTIC AGENTS; AZIRIDINES; CALORIMETRY, DIFFERENTIAL SCANNING; CHROMATOGRAPHY, GAS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG STABILITY; FREEZE DRYING; INDOLEQUINONES; MICROSCOPY, ELECTRON, SCANNING; SOLUBILITY; TERT-BUTYL ALCOHOL; VEHICLES; X-RAY DIFFRACTION;

EID: 34547912552     PISSN: None     EISSN: 15309932     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Bailey SM, Lewis AD, Patterson LH, Fisher GR, Knox RJ, Workman P. Involvement of NADPH: cytochrome P450 reductase in the activation of indoloquinone EO9 to free radical and DNA damaging species. Biochem Pharmacol. 2001;62:461-468.
2. Walton MI, Smith PJ, Workman P. The role of NAD(P)H: quinone reductase (EC 1.6.99.2, DT-diaphorase) in the reductive bioactivation of the novel indoloquinone antitumor agent EO9. Cancer Commun. 1991;3:199-206.
3. Hendriks HR, Pizao PE, Berger DP, et al. EO9: a novel bioreductive alkylating indoloquinone with preferential solid tumour activity and lack of bone marrow toxicity in preclinical models. Eur J Cancer. 1993;29:897-906.
4. Dass CR. Improving anti-angiogenic therapy via selective delivery of cationic liposomes to tumour vasculature. Int J Pharm. 2003; 267:1-12.
5. Jonkman-de Vries JD, Talsma H, Henrar REC, Kettenes-van den Bosch JJ, Bult A, Beijnen JH. Pharmaceutical formulation development of a parenteral lyophilized formulation of the novel indoloquinone antitumor agent EO9. Cancer Chemother Pharmacol. 1994;34:416-422.
6. Dirix LY, Tonnesen F, Cassidy J, et al. EO9 phase II study in advanced breast, gastric, pancreatic and colorectal carcinoma by the EORTC Early Clinical Studies Group. Eur J Cancer 1996;32:2019-2022.
7. Schellens JH, Dombernowsky P, Cassidy J, et al. Population pharmacokinetics and dynamics in phase II studies of the novel bioreductive alkylating cytotoxic indoloquinone EO9. Anticancer Drugs. 2001;12:583-590.
8. Phillips RM, Hulbert PB, Bibby MC, Sleigh NR, Double JA. In vitro activity of the novel indoloquinone EO-9 and the influence of pH on cytotoxicity. Br J Cancer. 1992;65:359-364.
9. Teagarden DL, Baker DS. Practical aspects of lyophilization using non-aqueous co-solvent systems. Eur J Pharm Sci. 2002; 15:115-133.
10. Ni N, Tesconi M, Tabibi SE, Gupta S, Yalkowsky SH. Use of pure t-butanol as a solvent for freeze-drying: a case study. Int J Pharm. 2001;226:39-46.
11. Kasraian K, DeLuca PP. Thermal analysis of the tertiary butyl alcohol-water system and its implications on freeze-drying. Pharm Res. 1995;12:484-490.
12. Wittaya-Areekul S, Nail SL. Freeze-drying of tert-butyl alcohol/water cosolvent systems: effects of formulation and process variables on residual solvents. J Pharm Sci. 1998;87:491-495.
13. Wittaya-Areekul S, Needham GF, Milton N, Roy ML, Nail SL. Freeze-drying of tert-butanol/water cosolvent systems: a case report on formation of a friable freeze-dried powder of tobramycin sulfate. J Pharm Sci. 2002;91:1147-1155.
14. Kasraian K, DeLuca PP. The effect of tertiary butyl alcohol on the resistance of the dry product layer during primary drying. Pharm Res. 1995;12:491-495.
15. Nuijen B, Bouma M, Henrar REC, et al. Pharmaceutical development of a parenteral lyophilized formulation of the novel antitumor agent aplidine. PDA J Pharm Sci Technol. 2000;54:193-208.
16. de Vries JD, Winkelhorst J, Underberg WJM, Henrar REC, Beijnen JH. A systematic study on the chemical stability of the novel indoloquinone antitumor agent EO9. Int J Pharm. 1993; 100:181-188.
17. Au JLS, Badalament RA, Guillaume Wientjes M, et al. Methods to improve efficacy of intravesical mitomycin C: results of a randomized phase III trial. J Natl Cancer Inst. 200 1;93:597-604.
18. Telang C, Suryanarayanan R. Crystallization of cephalothin sodium during lyophilization from tert-butyl alcohol-water cosolvent system. Pharm Res. 2005;22:153-160.
19. Telang C, Yu L, Suryanarayanan R. Effective inhibition of mannitol crystallization in frozen solutions by sodium chloride. Pharm Res. 2003;20:660-667.
20. Yu L, Milton N, Groleau EG, Mishra DS, Vansickle RE. Existence of a mannitol hydrate during freeze-drying and practical implications. J Pharm Sci. 1999;88:196-198.
21. Lindamood C, Farnell DR, Giles HD, et al. Subchronic toxicity studies of t-butyl alcohol in rats and mice. Fundam Appl Toxicol. 1992;19:91-100.
22. Pikal MJ, Shah S, Roy ML, Putman R. The secondary drying stage of freeze drying: drying kinetics as a function of temperature and chamber pressure. Int J Pharm. 1990;60:203-217.
23. Impurities: Guideline for Residual Solvents. ICH Topic Q3C. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use; Gaithersburg, MD: NIST; 1997
24. Telang C, Suryanarayanan R, Yu L. Crystallization of D-mannitol in binary mixtures with NaCl: phase diagram and polymorphism. Pharm Res. 2003;20:1939-1945.